Anatara Lifesciences Ltd (ASX:ANR) is pleased to release its Appendix 4D financial report for the half year ending 31st December 2018.
Anatara Lifesciences Ltd
Anatara Lifesciences (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing products for animal and human health. Following the successful licencing of our first product to leading global animal health company, Zoetis Inc, we are now focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders. For more information, please visit www.anataralifesciences.com.
Anatara Lifesciences (ASX:ANR) is pleased to release a copy of the presentation that Chief Executive Officer, Mr Steven Lydeamore, will be presenting at the Proactive Investors Australia CEO Sessions and the Wholesale Investor's Emergence 2019 conferences this month.
This month, Anatara's CEO, Steve Lydeamore will be presenting to investors at events in Sydney and Melbourne. We would like to extend to you the invitation to attend.
Anatara Lifesciences Ltd (ASX:ANR) is pleased to report positive efficacy data from its in vitro Proof of Concept studies of its Gastrointestinal ReProgramming product. GaRP is a unique natural dietary supplement designed to restore and maintain a healthy human gut and microbiome.
Anatara Lifesciences Ltd (ASX:ANR) is pleased to release its Appendix 4C for the quarter ending 31st December 2018. The Company's cash position at the end of the quarter stood at $1.5m. The Company also had $4,500,000 in deposits with terms of greater than 90 days. Expenditure during the quarter was in line with forecast.
Anatara Lifesciences (ASX:ANR) is pleased to announce the appointment of Dr. David Brookes as Non-Executive Director and Chair of the Audit and Risk Committee, effective from 23 January 2019.
PAC Partners Equity Research has released its latest research and valuation report on Anatara Lifesciences (ASX:ANR). The report provided a BUY rating and a 12-month price target of $1.40 per share.
Anatara Lifesciences (ASX:ANR) is pleased to announce that it has received $1,249,299 from the Australian Taxation Office under the Federal Government's Research and Development Tax Incentive scheme.
Anatara Lifesciences Ltd (ASX:ANR) provides the Company's Chairman Address to Shareholders.
Anatara Lifesciences (ASX:ANR) is pleased to announce that it has appointed Mr Steven Lydeamore as Chief Executive Officer, effective as of 3rd December 2018.